Trial Profile
A Phase I, Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of the BRAF Inhibitor GSK2118436 in Subjects With Solid Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Sep 2023
Price :
$35
*
At a glance
- Drugs Dabrafenib (Primary) ; Midazolam
- Indications Brain metastases; Colorectal cancer; Gastrointestinal stromal tumours; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Solid tumours; Thyroid cancer
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 06 Apr 2012 Actual patient number 184 added as reported by ClinicalTrials.gov.
- 06 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Feb 2012 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.